Search results
BridgeBio taps VCs for $200M, fueling oncology spinout's push to surpass KRAS class
FierceBiotech· 2 days agoBridgeBio Pharma has spun its Rolodex to fund a subset of its sprawling list of opportunities. Busy...
Moderna (MRNA) Gears Up for Q1 Earnings: Here's What to Expect
Zacks· 6 days agoInvestors' focus will likely be on updates on Moderna's (MRNA) expected RSV vaccine launch and its late-stage pipeline candidates when it reports first-quarter earnings.
Novo Nordisk (NYSE:NVO) and Eli Lilly (NYSE:LLY): Anti-Obesity Drug Market Could Reach Double...
The Wall Street Transcript· 6 days agoCiti Research Health Care Analyst Andrew Baum, M.D., maintains a “buy” recommendation on GLP-1...
Personalized Melanoma Vaccine Could Be a 'Game Changer' by Teaching the Body to Fight Cancer Cells
Smithsonian Magazine· 5 days agoA global trial has begun for the world’s first personalized vaccine for melanoma—the deadliest form of skin cancer, which affects about 132,000 people per year. If successful, the therapy will ...
Cantor Fitzgerald Brokers Boost Earnings Estimates for Merck & Co., Inc. (NYSE:MRK)
ETF DAILY NEWS· 5 days agoMerck & Co., Inc. (NYSE:MRK – Free Report) – Equities research analysts at Cantor Fitzgerald increased their FY2024 earnings per share (EPS) estimates for shares of Merck & Co., Inc. in a research ...
Merck & Co., Inc. (NYSE:MRK) Price Target Raised to $143.00
ETF DAILY NEWS· 5 days agoMerck & Co., Inc. (NYSE:MRK – Free Report) had its target price boosted by Truist Financial from $142.00 to $143.00 in a research report released on Friday, Benzinga reports. Truist Financial ...